ARTICLE DOWNLOAD

Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?

5$
ARTICLE DOWNLOAD

Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?

5$

Gilda Schmidt, Erich-Franz Solomayer, Rainer Maria Bohle, Christoph Gerlinger, Julia Caroline Radosa, Jan Endrikat & Mariz Kasoha 

Abstract

Objective

To evaluate the prognostic potential of vimentin, p53, EGFR, CK5/6, CK 14, and CK 17 in patients with triple-negative breast cancer (TNBC).

Material and methods

Tumor specimens of 60 patients with histologically confirmed TNBC were retrospectively analyzed. Formalin-fixed paraffin-embedded blocks of the tumor tissue were used to prepare tissue microarrays (TMAs). After immune-histochemical staining, protein expression of vimentin, p53, EGFR, CK5/6, CK 14, and CK 17 was determined and the immunoreactive score (IRS) was calculated. The protein expression was correlated to overall (OS) and disease-free survival (DFS).

Results

Ninety percent of patients suffered from an invasive ductal carcinoma T1 or T2, 66.7% were N0, and 70% had a G3 tumor with Ki67 of > 14%. Vimentin expression was found in 28/60 patients (46.7%), p53 expression in 30/60 patients (50%), and EGFR expression in 3/60 patients (5%). CK5/6, CK14, and CK17 expression was found in 60.0%, 63.3%, and 66.7%, respectively. Vimentin expression vs no expression was associated with significantly higher mean Ki67 values (52.5% vs. 31.1%; p = 0.0013) and significantly higher p53 expression (67.9% vs. 34.4%; p = 0.0097). No significant association between vimentin expression and OS (p = 0.7710) or DFS (p = 0.5558) was found during a mean follow-up of 92 months.

Conclusion

None of the six proteins proved to be suitable prognostic factors for OS and DSF in patients with TNBC.

Only units of this product remain
Year 2020
Language English
Format PDF
DOI 10.1007/s00432-020-03210-0